Terms: = Breast cancer AND KLF4, EZF, 9314, ENSG00000136826, GKLF, O43474
157 results:
1. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract] [Full Text] [Related]
2. miR-29a-klf4 signaling inhibits breast tumor initiation by regulating cancer stem cells.
Zhao Q; Shang Y; Lü J; Liu Y; Wang T; Li D; Li J; Lu Y; Wang Z; Yu Z
Int Immunopharmacol; 2024 Mar; 130():111797. PubMed ID: 38442582
[TBL] [Abstract] [Full Text] [Related]
3. Mechanisms of breast cancer Stem Cell Specification and Self-Renewal Mediated by Hypoxia-Inducible Factor 1.
Semenza GL
Stem Cells Transl Med; 2023 Dec; 12(12):783-790. PubMed ID: 37768037
[TBL] [Abstract] [Full Text] [Related]
4. EGR1 Regulation of Vasculogenic Mimicry in the MDA-MB-231 Triple-Negative breast cancer Cell Line through the Upregulation of klf4 Expression.
Jung E; Lee YH; Ou S; Kim TY; Shin SY
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762678
[TBL] [Abstract] [Full Text] [Related]
5. Estrogen-Related Receptor Alpha (ERRα) Promotes cancer Stem Cell-Like Characteristics in breast cancer.
Muduli K; Prusty M; Pradhan J; Samal AP; Sahu B; Roy DS; Reddy KS; Elangovan S
Stem Cell Rev Rep; 2023 Nov; 19(8):2807-2819. PubMed ID: 37584854
[TBL] [Abstract] [Full Text] [Related]
6. Targeting FOS attenuates malignant phenotypes of breast cancer: Evidence from in silico and in vitro studies.
Chang D; Li L; Xu Z; Chen X
J Biochem Mol Toxicol; 2023 Jul; 37(7):e23358. PubMed ID: 37016468
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.
Ma Y; Zhu Y; Shang L; Qiu Y; Shen N; Wang J; Adam T; Wei W; Song Q; Li J; Wicha MS; Luo M
Oncogene; 2023 May; 42(18):1419-1437. PubMed ID: 36922677
[TBL] [Abstract] [Full Text] [Related]
8. MED27 plays a tumor-promoting role in breast cancer progression by targeting klf4.
Wang R; Yu W; Zhu T; Lin F; Hua C; Ru L; Guo P; Wan X; Xue G; Guo Z; Han S; Lv K; Zhang G; Ge H; Guo W; Xu L; Deng W
Cancer Sci; 2023 Jun; 114(6):2277-2292. PubMed ID: 36786527
[TBL] [Abstract] [Full Text] [Related]
9. NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification.
Yang Y; Chen C; Zuo Q; Lu H; Salman S; Lyu Y; Huang TY; Wicks EE; Jackson W; Datan E; Wang R; Wang Y; Le N; Zhu Y; Qin W; Semenza GL
Sci Adv; 2022 Dec; 8(49):eabo5000. PubMed ID: 36490339
[TBL] [Abstract] [Full Text] [Related]
10. Redistribution of the SWI/SNF Complex Dictates Coordinated Transcriptional Control over Epithelial-Mesenchymal Transition of Normal breast Cells through TGF-β Signaling.
Jdeed S; Lengyel M; Uray IP
Cells; 2022 Aug; 11(17):. PubMed ID: 36078038
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulated FOXM1 signaling in the regulation of cancer stem cells.
Sher G; Masoodi T; Patil K; Akhtar S; Kuttikrishnan S; Ahmad A; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):107-121. PubMed ID: 35931301
[TBL] [Abstract] [Full Text] [Related]
12. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
13. A novel role for aspirin in enhancing the reprogramming function of miR-302/367 cluster and breast tumor suppression.
Rezania MA; Eghtedari A; Taha MF; Ardekani AM; Javeri A
J Cell Biochem; 2022 Jun; 123(6):1077-1090. PubMed ID: 35535453
[TBL] [Abstract] [Full Text] [Related]
14. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
15. Stem gene expression in breast tumors during chemotherapy: Connection with the main clinical and morphological factors and the disease outcome.
Ibragimova MK; Tsyganov MM; Deryusheva IV; Slonimskaya EM; Litviakov NV
J Cancer Res Ther; 2022; 18(1):89-95. PubMed ID: 35381768
[TBL] [Abstract] [Full Text] [Related]
16. Weighted correlation network analysis revealed novel long non-coding RNAs for colorectal cancer.
Chodary Khameneh S; Razi S; Shamdani S; Uzan G; Naserian S
Sci Rep; 2022 Feb; 12(1):2990. PubMed ID: 35194111
[TBL] [Abstract] [Full Text] [Related]
17. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract] [Full Text] [Related]
18. Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.
Sorrentino C; Ciummo SL; D'Antonio L; Fieni C; Lanuti P; Turdo A; Todaro M; Di Carlo E
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663639
[TBL] [Abstract] [Full Text] [Related]
19. Bioinformatics analysis of key genes and potential mechanism in cadmium-induced breast cancer progression.
Wu F; Zhang Y; Chen X; Wang Y; Peng H; Zhang Z; Yang Y; Wang Q
Environ Sci Pollut Res Int; 2022 Feb; 29(8):11883-11892. PubMed ID: 34558042
[TBL] [Abstract] [Full Text] [Related]
20. Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative breast cancer Cells.
Valla S; Hassan N; Vitale DL; Madanes D; Spinelli FM; Teixeira FCOB; Greve B; Espinoza-Sánchez NA; Cristina C; Alaniz L; Götte M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070901
[TBL] [Abstract] [Full Text] [Related]
[Next]
